Bristol-Myers Squibb Company
BMYNYSEAlpha Score of 63 reflects moderate overall profile with strong momentum, moderate value, weak quality, moderate sentiment.
Bristol-Myers Squibb Faces Revenue Headwinds Amidst Valuation and Quality Metrics
Apr 15, 2026Bristol-Myers Squibb (BMY) remains under pressure as investors weigh recent performance against a challenging growth profile. The company reported a significant year-over-year revenue decline of 22.0%, reflecting ongoing operational hurdles within the healthcare sector. Despite these top-line challenges, the stock maintains a P/E ratio of 16.87 and an EPS of 3.46, suggesting a valuation that currently sits in the middle of its 52-week range of $42.60 to $62.37. The Alpha Score of 57.4 highlights a disparity in underlying metrics, with a value sub-score of 68.4 and a momentum sub-score of 64.6 providing some stability, while the quality sub-score of 43.9 reflects the impact of the 14.6% net margin on overall corporate health. Sentiment remains neutral at 50, indicating that market participants are waiting for clearer signals before adjusting positions. The current data suggests a company balancing defensive valuation characteristics against the necessity for improved operational efficiency to reverse the recent revenue contraction. Investors should monitor upcoming quarterly earnings reports for signs of revenue stabilization or margin expansion.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Apr 1, 26 | Elkins David V | EVP, Chief Financial Officer | SELL | 25.5K | $1.6M |
| Apr 1, 26 | Elkins David V | EVP, Chief Financial Officer | SELL | 4.5K | $278K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Marshall Wace | 10.84M | $584.95M | NEW |
| Citadel Ken Griffin | 8.97M | $483.75M | NEW |
| Point72 Steve Cohen | 3.57M | $192.56M | NEW |
| Renaissance Technologies Jim Simons (founder) | 2.35M | $126.96M | NEW |
| D.E. Shaw David Shaw | 1.64M | $88.35M | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Mike Kelly R-PA | 2026-05-07 | sale | $15k – $50k |
| Gilbert Cisneros D-CA | 2025-12-19 | purchase | $1k – $15k |
| Julie Johnson D-TX | 2025-12-18 | sale | $1k – $15k |
| Gilbert Cisneros D-CA | 2025-11-12 | purchase | $1k – $15k |
| Jefferson Shreve R-IN | 2025-05-12 | sale | $15k – $50k |
| Julia Letlow R-LA | 2025-04-28 | sale | $1k – $15k |
| Julie Johnson D-TX | 2025-04-01 | sale | $1k – $15k |
| Greg Landsman D-OH | 2025-03-27 | sale | $1k – $15k |
Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its portfolio addresses critical therapeutic areas including oncology, hematology, immunology, cardiovascular disease, neuroscience, and other medical needs. Key products include Eliquis, which reduces the risk of stroke and systemic embolism in non-valvular atrial fibrillation and treats deep vein thrombosis and pulmonary embolism; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. With approximately 34,100 employees and headquarters in New York, the company generates substantial revenue, reporting trailing twelve-month figures of US$48.03 billion alongside earnings of US$6.04 billion. Bristol-Myers Squibb Company plays a pivotal role in advancing healthcare through its focus on high-unmet-need diseases, contributing to the pharmaceutical industry's efforts in oncology and immunology while maintaining strong financial health evidenced by robust gross margins and dividend capabilities.
Earnings calendar coming soon. Subscribe to get notified when BMY reports next.
Get earnings alerts →